We used a gerbil model of
otitis media to assess the efficacy of single-dose
ceftriaxone against three Streptococcus pneumoniae strains highly resistant to
penicillin (MICs, 4 to 8 micrograms/ml) and with various susceptibilities to
ceftriaxone (MICs, 0.5, 4, and 8 micrograms/ml). Middle ear
infection was induced by bilateral transbullar challenge with 10(7) bacteria per ear.
Antibiotic treatment was administered subcutaneously at 2 h postinfection.
Infection status was checked 2 days later by counting the bacteria in middle ear and cerebrospinal fluid samples. With the cefriaxone-susceptible strain (MIC, 0.5 microgram/ml), we tested doses of 5 to 100 mg/kg of
body weight. With a dose of 50 mg/kg, treatment outcome was equivalent to that with
amoxicillin, which was used as a reference (25 mg/kg, two
injections); no bacteria were recovered from 82% of the middle ear samples, and the rate of cerebrospinal fluid culture positivity was significantly reduced to 6%, relative to 59% for the untreated controls. Similar efficacy was obtained with a dose of 100 mg/kg against the two
ceftriaxone-resistant strains. Pharmacokinetic study indicates that the values of the parameters in plasma after the administration of a dose of 100 mg/kg (peak level of total
drug, 268 +/- 33 micrograms/ml; elimination half-life, 0.8 h; area under concentration-time curve, 488 micrograms.h.ml-1) were still suboptimal compared with the values of the parameters measured in pediatric patients after intravenous or intramuscular administration of a dose of 50 mg/kg. Our results indicate the efficacy of
ceftriaxone against experimental
cephalosporin-resistant pneumococcal
otitis and provide a basis for the clinical use of single-dose
ceftriaxone against pneumococcal
otitis media.